arrow_back Back to App

Limiting funding for diabetes and kidney disease research in 2024.

This bill aims to impose a strict spending cap on a key research agency focusing on diabetes, digestive, and kidney diseases for the 2024 fiscal year. This limitation could affect the pace and scope of medical research vital to millions of citizens suffering from these conditions. Citizens should be aware that reduced funding might slow down the discovery of new treatments and improvements in healthcare in these areas.
Key points
Sets a maximum spending limit for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for fiscal year 2024 at $2,029,823,000.
This restriction applies to funds allocated for scientific research and programs related to these common and serious diseases.
Potential consequence: slower progress in research on diabetes, obesity, kidney diseases, and other digestive ailments.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1978
Sponsor: Rep. Biggs, Andy [R-AZ-5]
Process start date: 2023-03-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To provide for a limitation on availability of funds for Department of Health and Human Services, National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases for fiscal year 2024.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1978.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-29.

What are the main provisions?

Key points include:

  • Sets a maximum spending limit for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for fiscal year 2024 at $2,029,823,000.
  • This restriction applies to funds allocated for scientific research and programs related to these common and serious diseases.
  • Potential consequence: slower progress in research on diabetes, obesity, kidney diseases, and other digestive ailments.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Biggs, Andy [R-AZ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health Public Investments